The Inflation Reduction Act (IRA) is poised to bring a significant transformation to the Medicare Part D benefit starting in 2025. This redesign will impact many stakeholders, including Part D sponsors, enrollees, pharmaceutical companies, and the Centers for Medicare & Medicaid Services (CMS). This article explores the key areas affected for each group, highlighting the significant changes and their implications.
Part D Sponsors
Increased Financial Burden
Enrollees who exceed an annual drug expenditure of approximately $6,230 ($520 monthly) will reach the $2,000 out-of-pocket cap within the plan year, eliminating the enrollee’s drug cost for the remainder of the year. While plan liabilities may remain stable or potentially decrease under the out-of-pocket cap, plans are obligated to cover 100% of all drug costs beyond the cap. Additionally, plans must continue to fully cover Advisory Committee on Immunization Practices (ACIP) vaccines and impose a maximum monthly copay of $35 for insulin products. CMS has reduced reinsurance payments for drug costs above the out-of-pocket cap, decreasing from 80% to 40% on generic drugs and from 80% to 20% on brand-name drugs. Furthermore, Part D sponsors are now required to implement the Medicare Prescription Payment Plan (M3P), which adds to their administrative responsibilities. Although CMS is offering increased monthly direct subsidy premiums, these changes collectively contribute to the anticipated rise in plan liability for CY 2025.
Enrollees
Reduced Out-of-Pocket Costs
Under the revamped Part D benefit, enrollees can look forward to multiple cost-saving opportunities at the pharmacy. Once an enrollee incurs $2,000 in out-of-pocket expenses, they will no longer have cost-sharing obligations for the remainder of the plan year. Additionally, enrollees will continue to benefit from $0 costs on adult vaccines recommended by the ACIP and a $35 monthly cap on insulin expenses.
Premium Increases
Despite CMS increasing direct subsidy payments to offset rising plan costs, premiums have risen due to expanded benefit coverage and administrative burdens. CMS introduced a premium stabilization program for Prescription Drug Plans (PDPs) and Employer Group Waiver Plans (EGWPs), allowing additional direct subsidy payments, enhanced risk-sharing protections, and capping annual premium increases at $35. Nearly all PDPs and EGWPs have opted into this program for CY 2025.
Pharmaceutical Companies
New Manufacturer Discount Program
The previous Coverage Gap Discount Program (CGDP) has been replaced with a new Manufacturer Discount Program. For applicable drugs in 2024, the CGDP was 70% of the ingredient cost in the coverage gap ($5,030 drug spend), applied to non-low-income enrollees, and stopped when the enrollee reached the catastrophic benefit phase. In 2025, the new manufacturer discount is 10% of the claim cost after the defined standard deductible ($590), applicable to all enrollees, and 20% in the catastrophic benefit phase for the rest of the plan year. This new program also allows a phase-in for Specified Manufacturers and/or Specified Small Manufacturers.
Drug Pricing
Additionally, CMS will continue the IRA drug inflation rebate program . This initiative mandates that manufacturers pay an inflation rebate if the prices of their drug products rise faster than the inflation rate over the same period. As a result, manufacturers will need to assess any potential price hikes to prevent triggering these inflation rebates.
CMS
Reduction in Reinsurance
Previously, CMS reimbursed 80% of drug costs above the $8,000 out-of-pocket limit. In 2025, reimbursement rates dropped to 20% for branded and 40% for generic products once the $2,000 limit is reached, shifting more liability to health plans.
Increased Direct Subsidy Payments
CMS has increased their direct subsidy payments to health plans, helping to cover additional administrative and coverage costs. The increase is largely due to the increase in industry premiums along with an IRA provision that increases the direct subsidy payment calculation.
As these changes take effect, stakeholders must adapt to the new landscape of Medicare Part D. Health plans, enrollees, pharmaceutical companies, and CMS will need to navigate these adjustments carefully to optimize outcomes and ensure compliance with the redesigned program.
Conclusion and Opportunities
The Medicare Part D redesign presents both challenges and opportunities for stakeholders. As the landscape shifts, there is a growing need for specialized training and consulting services to help organizations and individuals understand and adapt to these changes. Health plans and pharmaceutical companies can benefit from tailored training programs that focus on compliance, cost management, and strategic planning. Consulting services can assist in optimizing operational efficiencies and developing innovative solutions to navigate the complexities of the new Medicare Part D framework. By investing in these resources, stakeholders can not only ensure compliance but also leverage the redesign to enhance their strategic positioning in the healthcare market.
BluePeak can help!
Email BluePeak today at [email protected] to schedule a consultation.
